Provided by Tiger Fintech (Singapore) Pte. Ltd.

HCW Biologics Inc.

2.76
-0.2450-8.17%
Volume:33.30K
Turnover:96.78K
Market Cap:7.44M
PE:-0.16
High:3.02
Open:3.02
Low:2.61
Close:3.00
52wk High:100.80
52wk Low:2.30
Shares:2.70M
Float Shares:1.30M
Volume Ratio:0.65
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.5946
EPS(LYR):-30.9580
ROE:-27725.96%
ROA:-30.41%
PB:-143.21
PE(LYR):-0.09

Loading ...

HCW Biologics Q3 EPS $(2.02) Misses $1.58 Estimate, Sales $15.606M Beat $7.000M Estimate

Benzinga
·
Nov 15

HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040

Reuters
·
Nov 10

HCW Biologics announces data presented for TCE Program based on TRBC platform

TIPRANKS
·
Nov 07

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

GlobeNewswire
·
Nov 07

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment

GlobeNewswire
·
Oct 22

HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire
·
Oct 16

HCW Biologics Granted Nasdaq Extension to Regain Compliance with Listing Rules

Reuters
·
Oct 16

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

GlobeNewswire
·
Sep 30

Press Release: HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

Dow Jones
·
Sep 18

HCW Biologics’ Innovative Lead Candidate HCW11-040 Boosts Cancer Therapy Potential

TIPRANKS
·
Sep 18

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

GlobeNewswire
·
Sep 16

Consumer Sentiment, Oil Inventory Reports Set for Release as US Futures Little Changed in Friday's Premarket Session

MT Newswires Live
·
Sep 12

Top Premarket Gainers

MT Newswires Live
·
Sep 12

Why Is HCW Biologics Stock Surging 102% Overnight?

Benzinga
·
Sep 12

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

GlobeNewswire
·
Sep 09

Crude Oil Surges 2%; Chicago Fed National Activity Index Edges Lower in July

Benzinga
·
Aug 26

HCW Biologics Inc. (HCWB.US) Surges Nearly 70% Following Launch of Next-Generation Cancer Immunotherapy Platform

Stock News
·
Aug 25

HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform

Benzinga_recent_news
·
Aug 25

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

GlobeNewswire
·
Aug 25

HCW Biologics Inc. Faces Potential Nasdaq Delisting After Non-Compliance with Equity Rule

Reuters
·
Aug 20